(Q44665312)

5 December 2017

Characterization of a trimeric MPER containing HIV-1 gp41 antigen (English)

1 reference

5 December 2017

2

1 reference

5 December 2017

8

David Montefiori

1 reference

5 December 2017

Andreas Hinz

1

1 reference

5 December 2017

Heribert Quendler

3

1 reference

5 December 2017

David Lutje Hulsik

4

1 reference

5 December 2017

Gabi Stiegler

5

1 reference

5 December 2017

Hermann Katinger

6

1 reference

5 December 2017

Michael S Seaman

7

1 reference

5 December 2017

Winfried Weissenhorn

9

1 reference

5 December 2017

language of work or name

English

0 references

publication date

18 June 2009

1 reference

5 December 2017

1 reference

5 December 2017

390

1 reference

5 December 2017

2

1 reference

5 December 2017

221-227

1 reference

The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

HIV vaccine design and the neutralizing antibody problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Methods for reconstructing density maps of "single" particles from cryoelectron micrographs to subnanometer resolution.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Mechanism of membrane fusion by viral envelope proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Structural basis of viral invasion: lessons from paramyxovirus F

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Trimeric membrane-anchored gp41 inhibits HIV membrane fusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Measuring HIV neutralization in a luciferase reporter gene assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

One step membrane incorporation of viral antigens as a vaccine candidate against HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

7 January 2021

Toward an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Atomic structure of the ectodomain from HIV-1 gp41

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

7 January 2021

Virus membrane fusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

inferred from DOI database lookup

7 January 2021

based on heuristic

Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

inferred from DOI database lookup

7 January 2021

based on heuristic

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.015

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2009.05.015

1 reference

5 December 2017

1 reference